Psilocybin
Griffiths et al., Journal of Psychopharmacology, 2016
- Design
- Randomized, double-blind crossover trial comparing a high and a very low psilocybin dose.
- Who took part
- 51 adults with life-threatening cancer and anxiety or depression.
- Findings
- The high dose reduced depressed mood and anxiety, with many participants still showing clinically significant improvement about six months later.
- Limitations
- Crossover design means long-term comparisons have no untreated group. Small sample.
